Standard and emerging therapeutic approaches for thyroid malignancies

Area of Science:

• Oncology
• Endocrinology

Background:

• Differentiated thyroid cancer (DTC) is a common endocrine malignancy.
• Standard treatment involves surgery, radioiodine ablation, and hormone suppression, yielding excellent survival rates.
• Individualized therapy based on metastatic risk, patient factors, and recurrence monitoring presents ongoing challenges.

Purpose of the Study:

• To discuss the traditional approach to DTC treatment, highlighting areas of uncertainty.
• To review emerging therapeutic options for patients with metastatic DTC.
• To address considerations for high-risk patients, including those with genetic/environmental factors, extreme age, or comorbidities.

Main Methods:

• Literature review and synthesis of current clinical practices.
• Analysis of genetic aberrations driving DTC.
• Evaluation of novel and traditional therapeutic strategies.

Main Results:

• Standard DTC treatment ensures high overall survival.
• Controversies persist in tailoring therapy for metastatic risk and optimal recurrence management.
• Advances in understanding genetic drivers are enabling new treatments for metastatic disease.

Conclusions:

• While standard DTC treatment is effective, personalized approaches for risk stratification and recurrence are crucial.
• Emerging therapies offer new hope for patients with advanced or metastatic DTC.
• Continued research into genetic factors is vital for refining treatment strategies.